Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer

A. T. Zemplényi, Z. Kaló, G. Kovács, R. Farkas, T. Beöthe, D. Bányai, Z. Sebestyén, D. Endrei, I. Boncz, L. Mangel

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The aim of our analysis was to compare the cost-effectiveness of high-dose intensity-modulated radiation therapy (IMRT) and hypofractionated intensity-modulated radiation therapy (HF-IMRT) versus conventional dose three-dimensional radiation therapy (3DCRT) for the treatment of localised prostate cancer. A Markov model was constructed to calculate the incremental quality-adjusted life years and costs. Transition probabilities, adverse events and utilities were derived from relevant systematic reviews. Microcosting in a large university hospital was applied to calculate cost vectors. The expected mean lifetime cost of patients undergoing 3DCRT, IMRT and HF-IMRT were 7,160 euros, 6,831 euros and 6,019 euros respectively. The expected quality-adjusted life years (QALYs) were 5.753 for 3DCRT, 5.956 for IMRT and 5.957 for HF-IMRT. Compared to 3DCRT, both IMRT and HF-IMRT resulted in more health gains at a lower cost. It can be concluded that high-dose IMRT is not only cost-effective compared to the conventional dose 3DCRT but, when used with a hypofractionation scheme, it has great cost-saving potential for the public payer and may improve access to radiation therapy for patients.

Original languageEnglish
JournalEuropean Journal of Cancer Care
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Cost-Benefit Analysis
Prostatic Neoplasms
Radiotherapy
Costs and Cost Analysis
Therapeutics
Quality-Adjusted Life Years
Health

Keywords

  • Cost-effectiveness analysis
  • Hypofractionation
  • Prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. / Zemplényi, A. T.; Kaló, Z.; Kovács, G.; Farkas, R.; Beöthe, T.; Bányai, D.; Sebestyén, Z.; Endrei, D.; Boncz, I.; Mangel, L.

In: European Journal of Cancer Care, 2016.

Research output: Contribution to journalArticle

@article{78b7e8e62540433dbd9c4acecff5c837,
title = "Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer",
abstract = "The aim of our analysis was to compare the cost-effectiveness of high-dose intensity-modulated radiation therapy (IMRT) and hypofractionated intensity-modulated radiation therapy (HF-IMRT) versus conventional dose three-dimensional radiation therapy (3DCRT) for the treatment of localised prostate cancer. A Markov model was constructed to calculate the incremental quality-adjusted life years and costs. Transition probabilities, adverse events and utilities were derived from relevant systematic reviews. Microcosting in a large university hospital was applied to calculate cost vectors. The expected mean lifetime cost of patients undergoing 3DCRT, IMRT and HF-IMRT were 7,160 euros, 6,831 euros and 6,019 euros respectively. The expected quality-adjusted life years (QALYs) were 5.753 for 3DCRT, 5.956 for IMRT and 5.957 for HF-IMRT. Compared to 3DCRT, both IMRT and HF-IMRT resulted in more health gains at a lower cost. It can be concluded that high-dose IMRT is not only cost-effective compared to the conventional dose 3DCRT but, when used with a hypofractionation scheme, it has great cost-saving potential for the public payer and may improve access to radiation therapy for patients.",
keywords = "Cost-effectiveness analysis, Hypofractionation, Prostate cancer, Radiotherapy",
author = "Zempl{\'e}nyi, {A. T.} and Z. Kal{\'o} and G. Kov{\'a}cs and R. Farkas and T. Be{\"o}the and D. B{\'a}nyai and Z. Sebesty{\'e}n and D. Endrei and I. Boncz and L. Mangel",
year = "2016",
doi = "10.1111/ecc.12430",
language = "English",
journal = "European Journal of Cancer Care",
issn = "0961-5423",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer

AU - Zemplényi, A. T.

AU - Kaló, Z.

AU - Kovács, G.

AU - Farkas, R.

AU - Beöthe, T.

AU - Bányai, D.

AU - Sebestyén, Z.

AU - Endrei, D.

AU - Boncz, I.

AU - Mangel, L.

PY - 2016

Y1 - 2016

N2 - The aim of our analysis was to compare the cost-effectiveness of high-dose intensity-modulated radiation therapy (IMRT) and hypofractionated intensity-modulated radiation therapy (HF-IMRT) versus conventional dose three-dimensional radiation therapy (3DCRT) for the treatment of localised prostate cancer. A Markov model was constructed to calculate the incremental quality-adjusted life years and costs. Transition probabilities, adverse events and utilities were derived from relevant systematic reviews. Microcosting in a large university hospital was applied to calculate cost vectors. The expected mean lifetime cost of patients undergoing 3DCRT, IMRT and HF-IMRT were 7,160 euros, 6,831 euros and 6,019 euros respectively. The expected quality-adjusted life years (QALYs) were 5.753 for 3DCRT, 5.956 for IMRT and 5.957 for HF-IMRT. Compared to 3DCRT, both IMRT and HF-IMRT resulted in more health gains at a lower cost. It can be concluded that high-dose IMRT is not only cost-effective compared to the conventional dose 3DCRT but, when used with a hypofractionation scheme, it has great cost-saving potential for the public payer and may improve access to radiation therapy for patients.

AB - The aim of our analysis was to compare the cost-effectiveness of high-dose intensity-modulated radiation therapy (IMRT) and hypofractionated intensity-modulated radiation therapy (HF-IMRT) versus conventional dose three-dimensional radiation therapy (3DCRT) for the treatment of localised prostate cancer. A Markov model was constructed to calculate the incremental quality-adjusted life years and costs. Transition probabilities, adverse events and utilities were derived from relevant systematic reviews. Microcosting in a large university hospital was applied to calculate cost vectors. The expected mean lifetime cost of patients undergoing 3DCRT, IMRT and HF-IMRT were 7,160 euros, 6,831 euros and 6,019 euros respectively. The expected quality-adjusted life years (QALYs) were 5.753 for 3DCRT, 5.956 for IMRT and 5.957 for HF-IMRT. Compared to 3DCRT, both IMRT and HF-IMRT resulted in more health gains at a lower cost. It can be concluded that high-dose IMRT is not only cost-effective compared to the conventional dose 3DCRT but, when used with a hypofractionation scheme, it has great cost-saving potential for the public payer and may improve access to radiation therapy for patients.

KW - Cost-effectiveness analysis

KW - Hypofractionation

KW - Prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84957999147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957999147&partnerID=8YFLogxK

U2 - 10.1111/ecc.12430

DO - 10.1111/ecc.12430

M3 - Article

JO - European Journal of Cancer Care

JF - European Journal of Cancer Care

SN - 0961-5423

ER -